相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model
Liangru Zhou et al.
BMC PUBLIC HEALTH (2022)
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Fang-Hui Zhao et al.
LANCET INFECTIOUS DISEASES (2022)
Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?
Chau Quang et al.
TRENDS IN IMMUNOLOGY (2022)
Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study
Palmer Cody et al.
BMC INFECTIOUS DISEASES (2021)
Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study
Changfa Xia et al.
BMC MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial
You-Lin Qiao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
Rashidul Alam Mahumud et al.
PLOS ONE (2020)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Melanie Drolet et al.
LANCET (2019)
N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro
Minxi Wei et al.
EMERGING MICROBES & INFECTIONS (2018)
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial
Warner K. Huh et al.
LANCET (2017)
Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus
Jianhui Nie et al.
VIRUSES-BASEL (2016)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
Susanne Hartwig et al.
PAPILLOMAVIRUS RESEARCH (2015)
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
Silvia de Sanjose et al.
LANCET ONCOLOGY (2010)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine
Suzanne M. Garland et al.
JOURNAL OF INFECTIOUS DISEASES (2009)